

In the Claims:

Please amend the claims as follows. Applicant has included herewith a complete claim set with insertions and deletions indicated by underlining and strikethrough, respectively.

1. (Original) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ ID. NO. 1, or 2, characterised by an ability to complex with a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.
2. (Original) An isolated polypeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, characterised by an ability to elicit an immune response from human lymphocytes.
3. (Canceled)
4. (Currently amended) A nonapeptide comprising an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2, wherein the amino acid adjacent to the N-terminal amino acid is L or M, preferably L, and the C-terminal amino acid is L, V, or I, preferably L, other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57) as claimed in claim 4, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
5. (Currently amended) A nonapeptide as claimed in ~~either of claims 3 or claim 4~~, wherein the amino acid in position 3 is Y and/or the amino acid in position 4 is D and/or the amino acid in position 5 is G and/or the amino acid in position 7 is E and/or the amino acid in position 8 is H.
- 6-8. (Canceled)

9. (Currently amended) A nonapeptide having the amino acid sequence GLYDGMEHL (SEQ ID NO:42) or GLYDGREHS (SEQ ID NO:43), preferably GLYDGMEHL (SEQ ID NO:42).

10. (Currently amended) A decapeptide having the amino acid sequence GLYDGMEHLI (SEQ ID NO:44) or GLYDGREHSV (SEQ ID NO:45), preferably GLYDGMEHLI (SEQ ID NO:44).

11. (Previously presented) An isolated polypeptide of up to about 93 amino acids in length, characterised by comprising a nonapeptide as claimed in claim 4.

12. (Currently amended) A polypeptide as claimed in claim 11 comprising of an unbroken sequence of amino acids from SEQ. ID. NO. 1, or 2.

13-16. (Canceled)

17. (Previously presented) An isolated polypeptide or protein comprising a polypeptide as claimed in claim 1, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ. ID. NOs. 1 and 2 or that coded for by nucleotides 334-918 of SEQ. ID. NO. 7.

18. (Canceled)

19. (Currently amended) An isolated nucleic acid molecule molecules comprising a nucleotide sequence coding for a polypeptide or protein as claimed in claim 4, or a complementary nucleotide sequence, wherein said nucleotide sequence is not that set out in any of SEQ. ID. NOs. 3, 4, 5, 6 or 7.

20. (Original) A nucleic acid molecule as claimed in claim 19 and comprising an unbroken sequence of nucleotides from SEQ. ID. NO. 3,4 or 5, or a complimentary sequence, or an RNA transcript of said nucleic acid molecule.

21-25. (Canceled)

26. (Previously presented) A polypeptide binding agent which selectively binds or is specific for an isolated polypeptide or protein as claimed in claim 4.

27. (Previously presented) A polypeptide binding agent as claimed in claim 26, comprising an antibody, preferably a monoclonal antibody or an antibody fragment.

28. (Previously presented) A polypeptide binding agent which selectively binds or is specific for a complex of a polypeptide as claimed in claim 4 and a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1, but which does not bind said major histocompatibility complex molecule alone.

29. (Previously presented) A polypeptide binding agent as claimed in claim 28, comprising a cytolytic T-cell.

30. (Canceled)

31. (Previously presented) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in claim 11, optionally in admixture with a pharmaceutically acceptable carrier and optionally further comprising a major histocompatibility complex molecule type HLA-A2, preferably HLA-A2.1.

32. (Previously presented) A pharmaceutical composition for the prophylaxis, therapy or diagnosis of tumours comprising a polypeptide or protein as claimed in claim 11, complexed with a major histocompatibility complex molecule, HLA, and presented on the surface of an APC, preferably a dendritic cell, wherein said complex is formed by pulsing said APC with polypeptide or protein.

33. (Previously presented) A cell, preferably an APC, and more preferably, a dendritic cell, which has been pulsed with a polypeptide or protein as claimed in claim 11 to present on its surface said polypeptide or protein as a complex with a major histocompatibility complex molecule, HLA.

34. (Canceled)

35. (Previously presented) A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a polypeptide or protein as claimed in claim 11, and assaying for interaction between the agent and the polypeptide or protein, either free in or forming an integral part of the sample as a determination of the disease.

36. (Canceled)

37. (Previously presented) A method of producing a cytolytic T-cell culture reactive against tumour cells, comprising removing a lymphocyte sample from an individual and culturing the lymphocyte sample with a polypeptide or protein as claimed in claim 11.

38. (Previously presented) A product comprising T-cells reactive against a tumour cell expressing an antigen comprising a polypeptide or protein as claimed in claim 11, for use in the prophylaxis, therapy, or diagnosis of tumours.

39-40. (Canceled)

41. (Previously presented) A method of diagnosing disease, preferably cancer, comprising contacting a biological sample isolated from a subject with an agent that is specific for a nucleic acid molecule as claimed in claim 19 and assaying for interaction between the agent and the nucleic acid molecule either free in or forming an integral part of the sample as a determination of the disease.